Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor No significant financial relationships to disclose. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results